Dotarizine
Dotarizine is a drug used in the treatment of migraine,[1] which acts as a calcium channel blocker,[2] and also as an antagonist at the 5HT2A receptor, and to a lesser extent at the 5HT1A and 5HT2C receptors.[3][4] The anti-migraine action is thought to be due to its action as a vasodilator,[5][6] but it also has some anxiolytic effects[7] and blocks amnesia produced by electroconvulsive shock in animals.[8]
Clinical data | |
---|---|
Other names | Dotarizine |
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C29H34N2O2 |
Molar mass | 442.592 g/mol g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
|
References
- Ruiz-Nuño, A; Villarroya, M; Cano-Abad, M; Rosado, A; Balfagón, G; López, MG; García, AG (2001). "Mechanisms of blockade by the novel migraine prophylactic agent, dotarizine, of various brain and peripheral vessel contractility". European Journal of Pharmacology. 411 (3): 289–99. doi:10.1016/S0014-2999(00)00897-9. PMID 11164387.
- Ruiz-Nuño, A; Mayorgas, I; Hernández-Guijo, JM; Olivares, R; García, AG; Gandía, L (2003). "Antimigraine dotarizine blocks P/Q Ca2+ channels and exocytosis in a voltage-dependent manner in chromaffin cells". European Journal of Pharmacology. 481 (1): 41–50. doi:10.1016/j.ejphar.2003.09.013. PMID 14637173.
- Farré, M; Roset, PN; Llorente, M; Márquez, M; Albet, C; Pérez, JA; Herrero, E; Ortíz, JA (1997). "Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration". Methods and findings in experimental and clinical pharmacology. 19 (5): 343–50. PMID 9379783.
- Montiel, C; Herrero, CJ; García-Palomero, E; Renart, J; García, AG; Lomax, RB (1997). "Serotonergic effects of dotarizine in coronary artery and in oocytes expressing 5-HT2 receptors". European Journal of Pharmacology. 332 (2): 183–93. doi:10.1016/S0014-2999(97)01073-X. PMID 9286620.
- Kuridze, N; Gajkowska, B; Czernicki, Z; Jurkiewicz, J; Cervos-Navarro, J (1998). "The effect of Dotarizine--(Ca2+ channel blocker)--on vascular reactivity and ultrastructure of cerebral capillaries in animals subjected to anoxia". Folia Neuropathologica. 36 (2): 101–8. PMID 9757621.
- Kuridze, N; Czernicki, Z; Jarus-Dziedzic, K; Jurkiewicz, J; Cervos-Navarro, J (2000). "Regional differences of cerebrovascular reactivity effected by calcium channel blocker - dotarizine". Journal of the Neurological Sciences. 175 (1): 13–6. doi:10.1016/S0022-510X(00)00275-6. PMID 10785251.
- Petkov, VD; Belcheva, S; Konstantinova, E (1995). "Anxiolytic effects of dotarizine, a possible antimigraine drug". Methods and findings in experimental and clinical pharmacology. 17 (10): 659–68. PMID 9053586.
- Lazarova, M; Petkova, B; Petkov, VD (1995). "Effect of dotarizine on electroconvulsive shock or pentylenetetrazol-induced amnesia and on seizure reactivity in rats". Methods and findings in experimental and clinical pharmacology. 17 (1): 53–8. PMID 7623521.
Antimigraine preparations (N02C) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Analgesic/abortive |
| ||||||||||
Prophylactic |
| ||||||||||
|
Serotonin receptor modulators | |||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5-HT1 |
| ||||||||||||||||||||||||||||||||||||||
5-HT2 |
| ||||||||||||||||||||||||||||||||||||||
5-HT3–7 |
| ||||||||||||||||||||||||||||||||||||||
|
Simple piperazines (no additional rings) |
|
---|---|
Phenylpiperazines |
|
Benzylpiperazines | |
Diphenylalkylpiperazines (benzhydrylalkylpiperazines) |
|
Pyrimidinylpiperazines |
|
Pyridinylpiperazines |
|
Benzo(iso)thiazolylpiperazines | |
Tricyclics (piperazine attached via side chain) |
|
Others/Uncategorized |
|
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.